Macular Edema | ASweetLife

Novartis Drug Lucentis Approved by EU Commission for Treatment of Diabetic Macular Edema

The European Commission has granted Novartis a new indication for Lucentis (ranibizumab) to treat patients with visual impairment due to diabetic macular edema (DME) following two Novartis-sponsored clinical trials, RESTORE and RESOLVE. The trials showed that Lucentis was superior in providing rapid and sustained visual acuity gain versus placebo therapy or laser therapy..

Novartis Receives Positive Opinion on New Diabetic Macular Edema Drug

Novartis has announced that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis (ranibizumab) for the treatment of patients with visual impairment due to diabetic macular edema (DME). The submission was supported by data from two Novartis-funded clinical trials, RESTORE and RESOLVE, which showed that Lucentis...

Novartis’ Ranibizumab More Effective Than Laser Treatment in Treating Vision Loss due to Diabetic Macular Edema

Novartis announced that first results of the RESTORE Phase III study show that ranibizumab is significantly more effective than laser treatment, the current standard of care, at treating visual impairment due to diabetic macular edema (DME), a serious complication of diabetes. The one year results show that 37% of patients treated with ranibizumab 0.5 mg alone, and 43% of those treated with ranibizumab...

JDRF Funded Researchers Test Topical Drug to Treat Diabetic Macular Edema

The Juvenile Diabetes Research Foundation (JDRF) announced that researchers at the Wilmer Eye Institute of Johns Hopkins University School of Medicine in Maryland completed a multicenter human clinical trial treating diabetic macular edema with mecamylamine, a topical drug developed by the biotech company CoMentis, Inc. Funding for the study was provided by JDRF through its Industry Drug Development Partnership program...

First Treatment For Diabetic Related Eye Disease May Soon Be Available

According to a JDRF press release great progress has been made towards finding a treatment for diabetes-related eye disease. Novartis Pharmaceuticals, based in Switzerland, announced that the drug Lucentis has been submitted to the European Union's regulatory agency, European Medicines Agency, for approval for the treatment of diabetic macular edema...